Cordis, GenVec Collaborate On Cardiac Drug Delivery Trial To Begin Mid-2004

Intravascular delivery of GenVec's Biobypass angiogenic drug via Johnson & Johnson/Cordis' Myostar catheter will be evaluated in a 125-patient randomized trial featuring a "sham" placebo control